Adalimumab, Etanercept, Infliximab, Certolizumab Pegol, Golimumab, Tocilizumab and Abatacept for Rheumatoid Arthritis Not Previously Treated with Dmards Or Aft

Home , Abatacept, Golimumab, Tocilizumab

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or aft...

NICE NICE Standards Evidence Sign in  Pathways Guidance and indicators services



NICE uses cookies to make the site better. Learn more ×

Home  NICE Guidance  Published Guidance Adalimumab, etanercept, infiximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed

NICE technology appraisal guidance [TA375] Published date: January 2016

Guidance Tools and resources Information for the public History

Overview Guidance Share Download

1 Recommendations  Rheumatoid arthritis 2 Clinical need Next  and practice

3 The technologies Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, 4 Evidence and interpretation Remsina, Inflectra), certolizumab pegol (Cimzia), golimumab (Simponi), tocilizumab (RoActemra) and 5 Implementation abatacept (Orencia). These drugs are for people with 6 http://www.nice.org.uk/guidance/ta375[1/26/2016 2:49:16 PM] Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or aft... severe rheumatoid arthritis who have tried Recommendations conventional DMARDs only but they have not for research worked. 7 Related NICE guidance Guidance development process

8 Review of How we develop NICE technology appraisal guidance guidance This guidance replaces NICE technology appraisal guidance on: 9 Appraisal adalimumab, etanercept and infliximab for the treatment of Committee rheumatoid arthritis (TA130) members and certolizumab pegol for the treatment of rheumatoid arthritis NICE project (TA186) team golimumab for the treatment of methotrexate-naive rheumatoid 10 Sources of arthritis (TA224) and evidence abatacept for treating rheumatoid arthritis after the failure of considered by conventional disease-modifying anti-rheumatic drugs (TA280). the Committee It partially updates golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti- rheumatic drugs (TA225) and tocilizumab for the treatment of rheumatoid arthritis (TA247).

Next review date: January 2019

Next 

Get involved Explore Syndication services Register as a stakeholder Guidance About NICE http://www.nice.org.uk/guidance/ta375[1/26/2016 2:49:16 PM] Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or aft...

Citizens council Pathways  Access select CommunitiesConsultations Standards and services and Fellows and scholars indicators News content that NICE Join a committee Savings and provides in a ContactMeetings in uspublic productivity variety of formats. Student champions Evidence search Leave Tendersfeedback BNF Public involvement BNFC Guidance Jobs Clinical knowledge app summaries Journals and  Twitter  Android databases  YouTube  iOS  Linked-in

http://www.nice.org.uk/guidance/ta375[1/26/2016 2:49:16 PM]